nodes	percent_of_prediction	percent_of_DWPC	metapath
Sulfisoxazole—CYP2C9—urine—polycystic ovary syndrome	0.0459	0.159	CbGeAlD
Sulfisoxazole—EDNRA—Prostaglandin Synthesis and Regulation—PTGER3—polycystic ovary syndrome	0.0432	0.0612	CbGpPWpGaD
Sulfisoxazole—EDNRA—adrenal cortex—polycystic ovary syndrome	0.0367	0.127	CbGeAlD
Sulfisoxazole—EDNRA—endometrium—polycystic ovary syndrome	0.0328	0.114	CbGeAlD
Sulfisoxazole—EDNRA—uterus—polycystic ovary syndrome	0.0302	0.105	CbGeAlD
Sulfisoxazole—EDNRA—pituitary gland—polycystic ovary syndrome	0.0297	0.103	CbGeAlD
Sulfisoxazole—EDNRA—adipose tissue—polycystic ovary syndrome	0.0296	0.103	CbGeAlD
Sulfisoxazole—EDNRA—Endothelin Pathways—ADRA1A—polycystic ovary syndrome	0.0268	0.0379	CbGpPWpGaD
Sulfisoxazole—EDNRA—adrenal gland—polycystic ovary syndrome	0.0265	0.092	CbGeAlD
Sulfisoxazole—EDNRA—female gonad—polycystic ovary syndrome	0.0247	0.0858	CbGeAlD
Sulfisoxazole—EDNRA—vagina—polycystic ovary syndrome	0.0246	0.0852	CbGeAlD
Sulfisoxazole—EDNRA—Prostaglandin Synthesis and Regulation—CYP11A1—polycystic ovary syndrome	0.0212	0.0301	CbGpPWpGaD
Sulfisoxazole—EDNRA—Peptide GPCRs—LHCGR—polycystic ovary syndrome	0.021	0.0297	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCRs, Other—ADRA1D—polycystic ovary syndrome	0.0161	0.0229	CbGpPWpGaD
Sulfisoxazole—EDNRA—Prostaglandin Synthesis and Regulation—PRL—polycystic ovary syndrome	0.0158	0.0224	CbGpPWpGaD
Sulfisoxazole—EDNRA—Peptide GPCRs—FSHR—polycystic ovary syndrome	0.0154	0.0217	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCRs, Other—FSHR—polycystic ovary syndrome	0.013	0.0184	CbGpPWpGaD
Sulfisoxazole—EDNRA—Endothelin Pathways—GNAS—polycystic ovary syndrome	0.0129	0.0183	CbGpPWpGaD
Sulfisoxazole—EDNRA—Peptide ligand-binding receptors—NPB—polycystic ovary syndrome	0.0118	0.0167	CbGpPWpGaD
Sulfisoxazole—EDNRA—G alpha (q) signalling events—PTAFR—polycystic ovary syndrome	0.00935	0.0132	CbGpPWpGaD
Sulfisoxazole—EDNRA—G alpha (q) signalling events—ADRA1D—polycystic ovary syndrome	0.00907	0.0128	CbGpPWpGaD
Sulfisoxazole—EDNRA—G alpha (q) signalling events—ADRA1B—polycystic ovary syndrome	0.00883	0.0125	CbGpPWpGaD
Sulfisoxazole—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—PTAFR—polycystic ovary syndrome	0.00836	0.0118	CbGpPWpGaD
Sulfisoxazole—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—ADRA1D—polycystic ovary syndrome	0.00811	0.0115	CbGpPWpGaD
Sulfisoxazole—EDNRA—Class A/1 (Rhodopsin-like receptors)—NPB—polycystic ovary syndrome	0.00793	0.0112	CbGpPWpGaD
Sulfisoxazole—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—ADRA1B—polycystic ovary syndrome	0.00789	0.0112	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A1—polycystic ovary syndrome	0.00779	0.011	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCRs, Class A Rhodopsin-like—LHCGR—polycystic ovary syndrome	0.00772	0.0109	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCRs, Class A Rhodopsin-like—PTGER3—polycystic ovary syndrome	0.00772	0.0109	CbGpPWpGaD
Sulfisoxazole—CYP2C9—endocrine gland—polycystic ovary syndrome	0.00761	0.0264	CbGeAlD
Sulfisoxazole—EDNRA—GPCRs, Class A Rhodopsin-like—PTAFR—polycystic ovary syndrome	0.00722	0.0102	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A1—polycystic ovary syndrome	0.00709	0.01	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCRs, Class A Rhodopsin-like—ADRA1D—polycystic ovary syndrome	0.00701	0.00993	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Tamoxifen metabolism—SULT2A1—polycystic ovary syndrome	0.00686	0.00971	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCRs, Class A Rhodopsin-like—ADRA1B—polycystic ovary syndrome	0.00682	0.00966	CbGpPWpGaD
Sulfisoxazole—EDNRA—G alpha (q) signalling events—ADRA1A—polycystic ovary syndrome	0.00669	0.00947	CbGpPWpGaD
Sulfisoxazole—EDNRA—Class A/1 (Rhodopsin-like receptors)—PTGER3—polycystic ovary syndrome	0.00662	0.00937	CbGpPWpGaD
Sulfisoxazole—EDNRA—Class A/1 (Rhodopsin-like receptors)—LHCGR—polycystic ovary syndrome	0.00662	0.00937	CbGpPWpGaD
Sulfisoxazole—EDNRA—G alpha (q) signalling events—GNRH1—polycystic ovary syndrome	0.00622	0.00881	CbGpPWpGaD
Sulfisoxazole—EDNRA—Class A/1 (Rhodopsin-like receptors)—PTAFR—polycystic ovary syndrome	0.00619	0.00876	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCRs, Other—ADRB2—polycystic ovary syndrome	0.00619	0.00876	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR ligand binding—NPB—polycystic ovary syndrome	0.00604	0.00855	CbGpPWpGaD
Sulfisoxazole—EDNRA—Class A/1 (Rhodopsin-like receptors)—ADRA1D—polycystic ovary syndrome	0.00601	0.00851	CbGpPWpGaD
Sulfisoxazole—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—ADRA1A—polycystic ovary syndrome	0.00598	0.00847	CbGpPWpGaD
Sulfisoxazole—EDNRA—Class A/1 (Rhodopsin-like receptors)—ADRA1B—polycystic ovary syndrome	0.00584	0.00828	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCRs, Class A Rhodopsin-like—FSHR—polycystic ovary syndrome	0.00565	0.008	CbGpPWpGaD
Sulfisoxazole—Sulfathiazole—CYP19A1—polycystic ovary syndrome	0.00563	1	CrCbGaD
Sulfisoxazole—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—GNRH1—polycystic ovary syndrome	0.00556	0.00788	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCRs, Class A Rhodopsin-like—ADRA1A—polycystic ovary syndrome	0.00517	0.00732	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR ligand binding—PTGER3—polycystic ovary syndrome	0.00504	0.00714	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR ligand binding—LHCGR—polycystic ovary syndrome	0.00504	0.00714	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCRs, Class A Rhodopsin-like—ADRB3—polycystic ovary syndrome	0.00498	0.00705	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Constitutive Androstane Receptor Pathway—SULT2A1—polycystic ovary syndrome	0.00489	0.00693	CbGpPWpGaD
Sulfisoxazole—EDNRA—Class A/1 (Rhodopsin-like receptors)—FSHR—polycystic ovary syndrome	0.00484	0.00686	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR ligand binding—PTAFR—polycystic ovary syndrome	0.00471	0.00667	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR ligand binding—ADRA1D—polycystic ovary syndrome	0.00458	0.00648	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR ligand binding—ADRA1B—polycystic ovary syndrome	0.00445	0.0063	CbGpPWpGaD
Sulfisoxazole—EDNRA—Class A/1 (Rhodopsin-like receptors)—ADRA1A—polycystic ovary syndrome	0.00443	0.00627	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCRs, Class A Rhodopsin-like—MTNR1B—polycystic ovary syndrome	0.0044	0.00623	CbGpPWpGaD
Sulfisoxazole—EDNRA—Class A/1 (Rhodopsin-like receptors)—ADRB3—polycystic ovary syndrome	0.00426	0.00604	CbGpPWpGaD
Sulfisoxazole—EDNRA—Class A/1 (Rhodopsin-like receptors)—LHB—polycystic ovary syndrome	0.00421	0.00597	CbGpPWpGaD
Sulfisoxazole—EDNRA—G alpha (q) signalling events—GHRL—polycystic ovary syndrome	0.0042	0.00595	CbGpPWpGaD
Sulfisoxazole—EDNRA—Peptide ligand-binding receptors—GHRL—polycystic ovary syndrome	0.00415	0.00587	CbGpPWpGaD
Sulfisoxazole—EDNRA—Class A/1 (Rhodopsin-like receptors)—GNRH1—polycystic ovary syndrome	0.00412	0.00583	CbGpPWpGaD
Sulfisoxazole—EDNRA—Class A/1 (Rhodopsin-like receptors)—MTNR1B—polycystic ovary syndrome	0.00377	0.00533	CbGpPWpGaD
Sulfisoxazole—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—GHRL—polycystic ovary syndrome	0.00376	0.00532	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Xenobiotics—CYP1A1—polycystic ovary syndrome	0.00375	0.0053	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR ligand binding—FSHR—polycystic ovary syndrome	0.00369	0.00522	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Tamoxifen metabolism—CYP1A1—polycystic ovary syndrome	0.0036	0.0051	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR downstream signaling—NPB—polycystic ovary syndrome	0.00341	0.00483	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR ligand binding—ADRA1A—polycystic ovary syndrome	0.00337	0.00478	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR ligand binding—ADRB3—polycystic ovary syndrome	0.00325	0.0046	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR ligand binding—LHB—polycystic ovary syndrome	0.00321	0.00454	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR ligand binding—GNRH1—polycystic ovary syndrome	0.00314	0.00444	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling by GPCR—NPB—polycystic ovary syndrome	0.0031	0.00439	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR downstream signaling—PLEKHG5—polycystic ovary syndrome	0.00309	0.00437	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—ARHGAP30—polycystic ovary syndrome	0.00302	0.00428	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—ARHGAP23—polycystic ovary syndrome	0.00302	0.00428	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR ligand binding—SCT—polycystic ovary syndrome	0.00301	0.00426	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR ligand binding—MTNR1B—polycystic ovary syndrome	0.00287	0.00406	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Arachidonic acid metabolism—AKR1C3—polycystic ovary syndrome	0.00287	0.00406	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR downstream signaling—PTGER3—polycystic ovary syndrome	0.00285	0.00403	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR downstream signaling—LHCGR—polycystic ovary syndrome	0.00285	0.00403	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling by GPCR—PLEKHG5—polycystic ovary syndrome	0.0028	0.00397	CbGpPWpGaD
Sulfisoxazole—EDNRA—Class A/1 (Rhodopsin-like receptors)—GHRL—polycystic ovary syndrome	0.00278	0.00394	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCRs, Class A Rhodopsin-like—ADRB2—polycystic ovary syndrome	0.00269	0.00381	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR downstream signaling—PTAFR—polycystic ovary syndrome	0.00266	0.00377	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP11A1—polycystic ovary syndrome	0.00262	0.00371	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Oxidation by Cytochrome P450—CYP11A1—polycystic ovary syndrome	0.00259	0.00366	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling by GPCR—PTGER3—polycystic ovary syndrome	0.00259	0.00366	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling by GPCR—LHCGR—polycystic ovary syndrome	0.00259	0.00366	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR downstream signaling—ADRA1D—polycystic ovary syndrome	0.00259	0.00366	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR downstream signaling—ADRA1B—polycystic ovary syndrome	0.00252	0.00356	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metapathway biotransformation—AKR1C2—polycystic ovary syndrome	0.00246	0.00348	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP17A1—polycystic ovary syndrome	0.00244	0.00345	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling by GPCR—PTAFR—polycystic ovary syndrome	0.00242	0.00343	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Oxidation by Cytochrome P450—CYP17A1—polycystic ovary syndrome	0.00241	0.00341	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling by GPCR—ADRA1D—polycystic ovary syndrome	0.00235	0.00333	CbGpPWpGaD
Sulfisoxazole—EDNRA—Class A/1 (Rhodopsin-like receptors)—ADRB2—polycystic ovary syndrome	0.0023	0.00326	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR downstream signaling—PDE3B—polycystic ovary syndrome	0.00229	0.00324	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling by GPCR—ADRA1B—polycystic ovary syndrome	0.00228	0.00323	CbGpPWpGaD
Sulfisoxazole—EDNRA—Peptide ligand-binding receptors—POMC—polycystic ovary syndrome	0.00214	0.00303	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Phase 1 - Functionalization of compounds—CYP11A1—polycystic ovary syndrome	0.00213	0.00301	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR ligand binding—GHRL—polycystic ovary syndrome	0.00212	0.003	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—FLT4—polycystic ovary syndrome	0.00209	0.00297	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR downstream signaling—FSHR—polycystic ovary syndrome	0.00208	0.00295	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling by GPCR—PDE3B—polycystic ovary syndrome	0.00208	0.00294	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Phase 1 - Functionalization of compounds—CYP17A1—polycystic ovary syndrome	0.00198	0.0028	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP19A1—polycystic ovary syndrome	0.00193	0.00273	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR downstream signaling—ADRA1A—polycystic ovary syndrome	0.00191	0.0027	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Oxidation by Cytochrome P450—CYP19A1—polycystic ovary syndrome	0.0019	0.0027	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling by GPCR—FSHR—polycystic ovary syndrome	0.00189	0.00268	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—polycystic ovary syndrome	0.00185	0.00262	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR downstream signaling—ADRB3—polycystic ovary syndrome	0.00183	0.0026	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—NPB—polycystic ovary syndrome	0.00183	0.00259	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR downstream signaling—LHB—polycystic ovary syndrome	0.00181	0.00257	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Arachidonic acid metabolism—CYP1A1—polycystic ovary syndrome	0.0018	0.00255	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR downstream signaling—GNRH1—polycystic ovary syndrome	0.00177	0.00251	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR ligand binding—ADRB2—polycystic ovary syndrome	0.00175	0.00248	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling by GPCR—ADRA1A—polycystic ovary syndrome	0.00173	0.00245	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR downstream signaling—SCT—polycystic ovary syndrome	0.0017	0.00241	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling by GPCR—ADRB3—polycystic ovary syndrome	0.00167	0.00236	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—PLEKHG5—polycystic ovary syndrome	0.00166	0.00234	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling by GPCR—LHB—polycystic ovary syndrome	0.00165	0.00233	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR ligand binding—GNAS—polycystic ovary syndrome	0.00163	0.0023	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR downstream signaling—MTNR1B—polycystic ovary syndrome	0.00162	0.0023	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling by GPCR—GNRH1—polycystic ovary syndrome	0.00161	0.00228	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Phase 1 - Functionalization of compounds—CYP19A1—polycystic ovary syndrome	0.00156	0.00221	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1A1—polycystic ovary syndrome	0.00156	0.0022	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling by GPCR—SCT—polycystic ovary syndrome	0.00154	0.00218	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Oxidation by Cytochrome P450—CYP1A1—polycystic ovary syndrome	0.00153	0.00217	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—LHCGR—polycystic ovary syndrome	0.00153	0.00216	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—PTGER3—polycystic ovary syndrome	0.00153	0.00216	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling by GPCR—MTNR1B—polycystic ovary syndrome	0.00147	0.00208	CbGpPWpGaD
Sulfisoxazole—EDNRA—Class A/1 (Rhodopsin-like receptors)—POMC—polycystic ovary syndrome	0.00144	0.00204	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—PTAFR—polycystic ovary syndrome	0.00143	0.00202	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—ADRA1D—polycystic ovary syndrome	0.00139	0.00196	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metapathway biotransformation—AKR1C1—polycystic ovary syndrome	0.00137	0.00193	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—ADRA1B—polycystic ovary syndrome	0.00135	0.00191	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—INHBB—polycystic ovary syndrome	0.00131	0.00186	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Biological oxidations—SULT2A1—polycystic ovary syndrome	0.00127	0.00181	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Phase 1 - Functionalization of compounds—CYP1A1—polycystic ovary syndrome	0.00126	0.00179	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metapathway biotransformation—SULT2A1—polycystic ovary syndrome	0.00126	0.00178	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—PDE3B—polycystic ovary syndrome	0.00123	0.00174	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism of lipids and lipoproteins—LPCAT2—polycystic ovary syndrome	0.00121	0.00171	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR downstream signaling—GHRL—polycystic ovary syndrome	0.0012	0.0017	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Cytochrome P450 - arranged by substrate type—POMC—polycystic ovary syndrome	0.00116	0.00164	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Biological oxidations—CYP11A1—polycystic ovary syndrome	0.00113	0.0016	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—FSHR—polycystic ovary syndrome	0.00112	0.00158	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metapathway biotransformation—CYP11A1—polycystic ovary syndrome	0.00111	0.00158	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR ligand binding—POMC—polycystic ovary syndrome	0.00109	0.00155	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling by GPCR—GHRL—polycystic ovary syndrome	0.00109	0.00154	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metapathway biotransformation—AKR1C3—polycystic ovary syndrome	0.00105	0.00149	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—RACGAP1—polycystic ovary syndrome	0.00105	0.00149	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Biological oxidations—CYP17A1—polycystic ovary syndrome	0.00105	0.00149	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metapathway biotransformation—CYP17A1—polycystic ovary syndrome	0.00104	0.00147	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—ADRA1A—polycystic ovary syndrome	0.00102	0.00145	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—FST—polycystic ovary syndrome	0.000996	0.00141	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR downstream signaling—ADRB2—polycystic ovary syndrome	0.000991	0.0014	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—ADRB3—polycystic ovary syndrome	0.000984	0.00139	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—LHB—polycystic ovary syndrome	0.000973	0.00138	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C2—polycystic ovary syndrome	0.000956	0.00135	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism of lipids and lipoproteins—TEAD2—polycystic ovary syndrome	0.000956	0.00135	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—GNRH1—polycystic ovary syndrome	0.000951	0.00135	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Phase 1 - Functionalization of compounds—POMC—polycystic ovary syndrome	0.00094	0.00133	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—AKR1C1—polycystic ovary syndrome	0.000921	0.0013	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR downstream signaling—GNAS—polycystic ovary syndrome	0.000919	0.0013	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—SCT—polycystic ovary syndrome	0.000911	0.00129	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling by GPCR—ADRB2—polycystic ovary syndrome	0.0009	0.00127	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—MTNR1B—polycystic ovary syndrome	0.000869	0.00123	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—FGF18—polycystic ovary syndrome	0.000854	0.00121	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—RBP4—polycystic ovary syndrome	0.000847	0.0012	CbGpPWpGaD
Sulfisoxazole—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—polycystic ovary syndrome	0.000844	0.00119	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling by GPCR—GNAS—polycystic ovary syndrome	0.000834	0.00118	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Biological oxidations—CYP19A1—polycystic ovary syndrome	0.000831	0.00118	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metapathway biotransformation—CYP19A1—polycystic ovary syndrome	0.000819	0.00116	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism of lipids and lipoproteins—PNPLA2—polycystic ovary syndrome	0.000801	0.00113	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—YAP1—polycystic ovary syndrome	0.000791	0.00112	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—GAB1—polycystic ovary syndrome	0.00078	0.0011	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism of lipids and lipoproteins—SRD5A1—polycystic ovary syndrome	0.00076	0.00108	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—INSR—polycystic ovary syndrome	0.000746	0.00106	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism of lipids and lipoproteins—STAR—polycystic ovary syndrome	0.000725	0.00103	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—AKR1C3—polycystic ovary syndrome	0.000709	0.001	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—TNRC6B—polycystic ovary syndrome	0.000698	0.000988	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—PGR—polycystic ovary syndrome	0.000691	0.000978	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Biological oxidations—CYP1A1—polycystic ovary syndrome	0.00067	0.000948	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metapathway biotransformation—CYP1A1—polycystic ovary syndrome	0.00066	0.000935	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—PLAT—polycystic ovary syndrome	0.000642	0.000909	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—GHRL—polycystic ovary syndrome	0.000642	0.000909	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR downstream signaling—POMC—polycystic ovary syndrome	0.000619	0.000876	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism of lipids and lipoproteins—HSD3B1—polycystic ovary syndrome	0.000616	0.000873	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—ATF1—polycystic ovary syndrome	0.000613	0.000868	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—TCF7L2—polycystic ovary syndrome	0.000597	0.000846	CbGpPWpGaD
Sulfisoxazole—EDNRA—GPCR downstream signaling—AKT2—polycystic ovary syndrome	0.000595	0.000842	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—NMNAT3—polycystic ovary syndrome	0.000589	0.000834	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—NGFR—polycystic ovary syndrome	0.000565	0.000801	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism of lipids and lipoproteins—LHB—polycystic ovary syndrome	0.000562	0.000796	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling by GPCR—POMC—polycystic ovary syndrome	0.000562	0.000796	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—PRL—polycystic ovary syndrome	0.00056	0.000793	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism of lipids and lipoproteins—HSD3B2—polycystic ovary syndrome	0.000549	0.000778	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling by GPCR—AKT2—polycystic ovary syndrome	0.00054	0.000765	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—LPCAT2—polycystic ovary syndrome	0.000539	0.000763	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—SUOX—polycystic ovary syndrome	0.000539	0.000763	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C1—polycystic ovary syndrome	0.000532	0.000753	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—ADRB2—polycystic ovary syndrome	0.000532	0.000753	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—ISYNA1—polycystic ovary syndrome	0.000501	0.000709	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Biological oxidations—POMC—polycystic ovary syndrome	0.000499	0.000707	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—GNAS—polycystic ovary syndrome	0.000493	0.000698	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism of lipids and lipoproteins—SULT2A1—polycystic ovary syndrome	0.00049	0.000693	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—NCOR1—polycystic ovary syndrome	0.00047	0.000665	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—NRG1—polycystic ovary syndrome	0.000461	0.000653	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism of lipids and lipoproteins—YAP1—polycystic ovary syndrome	0.000457	0.000647	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism of lipids and lipoproteins—CYP11A1—polycystic ovary syndrome	0.000434	0.000614	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—AKR1C2—polycystic ovary syndrome	0.000426	0.000603	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—TEAD2—polycystic ovary syndrome	0.000426	0.000603	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C3—polycystic ovary syndrome	0.000409	0.00058	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism of lipids and lipoproteins—CYP17A1—polycystic ovary syndrome	0.000403	0.000571	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—IRS2—polycystic ovary syndrome	0.000395	0.000559	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—LEP—polycystic ovary syndrome	0.000386	0.000547	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—PNPLA2—polycystic ovary syndrome	0.000357	0.000505	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—IRS1—polycystic ovary syndrome	0.000345	0.000488	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—SRD5A1—polycystic ovary syndrome	0.000338	0.000479	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—POMC—polycystic ovary syndrome	0.000332	0.00047	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—INS—polycystic ovary syndrome	0.00033	0.000467	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—STAR—polycystic ovary syndrome	0.000323	0.000457	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—IGF1—polycystic ovary syndrome	0.000319	0.000452	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—polycystic ovary syndrome	0.000319	0.000452	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—AKT2—polycystic ovary syndrome	0.000319	0.000452	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—SERPINE1—polycystic ovary syndrome	0.000303	0.000429	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—HMMR—polycystic ovary syndrome	0.000288	0.000407	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—HSD3B1—polycystic ovary syndrome	0.000274	0.000389	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—polycystic ovary syndrome	0.000271	0.000384	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—polycystic ovary syndrome	0.000257	0.000364	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—LHB—polycystic ovary syndrome	0.00025	0.000354	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—HSD3B2—polycystic ovary syndrome	0.000245	0.000346	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling by GPCR—IL6—polycystic ovary syndrome	0.000244	0.000346	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—AKR1C1—polycystic ovary syndrome	0.000237	0.000335	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—SULT2A1—polycystic ovary syndrome	0.000218	0.000309	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—RRM2—polycystic ovary syndrome	0.000211	0.000299	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—VEGFA—polycystic ovary syndrome	0.000209	0.000295	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—YAP1—polycystic ovary syndrome	0.000204	0.000288	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—NAMPT—polycystic ovary syndrome	0.000196	0.000277	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	0.000194	0.000275	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—CYP11A1—polycystic ovary syndrome	0.000193	0.000273	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	0.000192	0.000272	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—AKR1C3—polycystic ovary syndrome	0.000182	0.000258	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—CYP17A1—polycystic ovary syndrome	0.00018	0.000254	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—TH—polycystic ovary syndrome	0.000155	0.00022	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—SLC2A4—polycystic ovary syndrome	0.000151	0.000214	CbGpPWpGaD
Sulfisoxazole—EDNRA—Signaling Pathways—IL6—polycystic ovary syndrome	0.000144	0.000204	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—CYP19A1—polycystic ovary syndrome	0.000142	0.000201	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—GNAS—polycystic ovary syndrome	0.000127	0.00018	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—NCOR1—polycystic ovary syndrome	0.000121	0.000171	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—CYP1A1—polycystic ovary syndrome	0.000115	0.000162	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—MTHFR—polycystic ovary syndrome	0.000107	0.000151	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—PPARG—polycystic ovary syndrome	8.66e-05	0.000123	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—POMC—polycystic ovary syndrome	8.54e-05	0.000121	CbGpPWpGaD
Sulfisoxazole—CYP2C9—Metabolism—INS—polycystic ovary syndrome	8.49e-05	0.00012	CbGpPWpGaD
